Evogene (EVGN) said Monday it has struck a deal for ICL to acquire the majority of activity of its subsidiary, Lavie Bio, which focuses on improving agriculture productivity.
The company said ICL will also acquire its MicroBoost AI for AG platform as part of the agreement.
Evogene said key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, microbial bank and data assets. It expects to close the deal in Q2.
"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said Chief Executive Ofer Haviv.
The shares shares were up about 20% in recent trading.
Price: 1.17, Change: +0.20, Percent Change: +20.62
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.